{"id":14165,"date":"2010-12-01T09:04:16","date_gmt":"2010-12-01T09:04:16","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=14165"},"modified":"2012-07-26T15:09:30","modified_gmt":"2012-07-26T15:09:30","slug":"conference-reports-and-online-abstracts-3","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/14165","title":{"rendered":"Conference reports and online abstracts"},"content":{"rendered":"<h2>4th International Workshop on HIV Persistence during Therapy<\/h2>\n<p>8-11 December 2009<\/p>\n<p>Every other year since 2003, researcher\u00a0Alain Lafeuillade has chaired a workshop on HIV persistence during therapy. The goal of the meeting is to work toward strategies for curing HIV infection, either by eradicating the virus or inducing long-term control of viral replication in the absence of ongoing treatment. The fourth meeting was held in December of 2009, and abstracts and selected slide presentations are now available online.<\/p>\n<p>Final Program and Abstract Book<a href=\"http:\/\/www.ihlpress.com\/pdf%20files\/AbstractBook_PW2009_111009.pdf\"> http:\/\/www.ihlpress.com\/pdf files\/AbstractBook_PW2009_111009.pdf<\/a><\/p>\n<p>Selected Slide Presentations <a href=\"http:\/\/www.ihlpress.com\/gaj_persistence2009.html\">http:\/\/www.ihlpress.com\/gaj_persistence2009.html<\/a><\/p>\n<h2>Emerging Issues in clinical trials for new ARV development<\/h2>\n<p><strong>Forum for Collaborative HIV Research (FCHR)<\/strong><\/p>\n<p>Details and presentations from the Forum\u0092s roundtable on 30 September 30, 2010.<\/p>\n<p>Objectives:<\/p>\n<ul>\n<li>To discuss general developments with non-inferiority margins and adaptive design in clinical trials and regulatory experience.<\/li>\n<li>To provide perspectives on recent clinical trial experiences with investigational HIV agents.<\/li>\n<li>To propose new models to study investigational HIV agents in clinical trials and discuss possible solutions to commonly encountered issues in clinical trials.<\/li>\n<li>To discuss the need for trials in treatment naive patients, dose-finding and identification of biomarkers for longer term safety evaluations.<\/li>\n<\/ul>\n<p><a href=\"http:\/\/hivforum.us1.list-manage.com\/track\/click?u=57bb4a7a73d2cce9128afb09b&amp;id=259573778e&amp;e=ffb9e298b4\">http:\/\/hivforum.us1.list-manage.com\/track\/click?u=57bb4a7a73d2cce9128afb09b&amp;id=259573778e&amp;e=ffb9e298b4<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>4th International Workshop on HIV Persistence during Therapy 8-11 December 2009 Every other year since 2003, researcher\u00a0Alain Lafeuillade has chaired a workshop on HIV persistence during therapy. The goal of the meeting is to work toward strategies for curing HIV &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[],"class_list":["post-14165","post","type-post","status-publish","format-standard","hentry","category-on-the-web"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/14165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=14165"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/14165\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=14165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=14165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=14165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}